Filter Results :

Your search for Biosimilars returned 65 reports

Sort by


Biosimilars: US Payer Perspectives

01 Apr 2015  |  Published by:  FirstWord
Biosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and provides detailed and actionable insights from 12 expert US payers from a range of different organisations, including Pharmacy Benefit Managers, Managed Care Organisations and Integrated Delivery Networks. In...

$ 2,100.00

Read More

Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

01 Apr 2015  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of A...

$ 1,413.41

Read More

Competitor Analysis: EGF-R Antibodies 2015 - Biosuperiors and Biosimilars of Erbitux

28 Mar 2015  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about EGF-R Antibodies 2015 Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015. Purchase of the downloa...

$ 271.81

Read More

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

25 Mar 2015  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015. Purchase of...

$ 326.17

Read More

Competitor Analysis: TNF Antibodies 2015 - Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

22 Mar 2015  |  Published by:  La Merie Business Intelligence
The present Competitive Intelligence report about TNF Antibodies 2015 Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflamma...

$ 543.62

Read More

2015 Deep Research Report on Global Biologics and Biosimilars Industry

03 Mar 2015  |  Published by:  QYResearch
Summary  2015 Deep Research Report on Global Biologics and Biosimilars Industry is a professional and depth research report on Global Biologics and Biosimilars industry.  For overview analysis, the report introduces Biologics and Biosimilars basic information including definition, ...

$ 2,600.00

Read More

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

15 Feb 2015  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downl...

$ 326.17

Read More

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis

08 Feb 2015  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) used to treat ...

$ 380.53

Read More

2015 Market Research Report on Global Biologics and Biosimilars Industry

02 Feb 2015  |  Published by:  QYResearch
2015 Market Research Report on Global Biologics and Biosimilars Industry is a professional and depth research report on Global Biologics and Biosimilars industryFor overview analysis, the report introduces Biologics and Biosimilars basic information including definition, classification, application,...

$ 2,600.00

Read More

Japan Pharma Outlook 2015: 2015 - Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

27 Jan 2015  |  Published by:  MP Advisors
The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations. For the inn...

$ 2,000.00

Read More

Biosimilars: European Payer Perspectives

06 Jan 2015  |  Published by:  FirstWord
Cost is king when it comes to European biosimilars. One issue unites European healthcare payers: the need to provide biosimilars at the most affordable price in cash constrained health services. Biosimilars: European Payer Perspect...

$ 1,950.00

Read More

Biosimilars: Global Markets

01 Jan 2015  |  Published by:  BCC Research
The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate (CAGR) of 15% from 2014 through 2019. This report provides:-An overview of the global market for bi...

$ 6,650.00

Read More

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

31 Dec 2014  |  Published by:  GlobalData
SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expe...

$ 3,495.00

Read More

Global Oncology Biosimilars Market 2014-2018

19 Nov 2014  |  Published by:  Technavio
Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to ...

$ 2,500.00

Read More

Europe Biosimilars Market & Pipeline Insight

08 Oct 2014  |  Published by:  KuicK Research
Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with f...

$ 2,400.00

Read More
Total 65 records.